LEGN Legend Biotech Corp

Legend Biotech Corporation (NASDAQ:LEGN) has received a consensus "Moderate Buy" rating from twelve analysts, with an average 12-month price target of $68.10. The company reported EPS of ($0.11), beating estimates, and revenue of $272.3 million, a 70% year-over-year increase. Institutional investors own 70.89% of the stock, and several hedge funds have recently increased their holdings.

Legend Biotech (LEGN) is highlighted as a promising mid-cap healthcare stock with significant upside potential, according to analyst ratings. Despite a 33% drop in 2025, 10 out of 11 analysts recommend a "Buy," predicting a 211% upside potential from current levels. Cantor Fitzgerald analyst Eric Schmidt reaffirmed an "Overweight" stance, citing management's confidence in their CAR-T cell therapy, Carvykti, for myeloma treatment and increasing market demand.

New long-term safety data for Legend Biotech's CARVYKTI, including neurologic toxicity with parkinsonism and significant tocilizumab use, adds important context to its risk-benefit profile. While these findings sharpen the safety picture, they don't immediately alter the focus on CARVYKTI's commercial execution and pipeline progress. Investors should be aware of the evolving safety profile as they evaluate Legend's future earnings and valuation, especially given concentration in a single commercial product.

Legend Biotech has released new long-term data for its CAR T therapy CARVYKTI from the CARTITUDE program, clarifying its durability, safety, and future revenue potential in multiple myeloma. Despite positive updates for CARVYKTI, the company's share price has seen significant declines over the past month and year, though a recent daily gain suggests a potential stabilization in investor sentiment. The market narrative suggests LEGN is undervalued, with a fair value of $74.51 against its last close of $21.92, driven by expectations of strong revenue and margin expansion, although competition and reliance on CARVYKTI pose risks.

Legend Biotech Corporation announced that its CEO, Ying Huang, Ph.D., will present company updates at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be available via live webcast and a replay on the company's Investor Relations section of their website. Legend Biotech is a leader in cell therapy, known for its CAR-T cell therapy CARVYKTI, developed with Johnson & Johnson.

This article identifies three oversold healthcare stocks—Insmed Inc (NASDAQ: INSM), Tempus AI Inc (NASDAQ: TEM), and Legend Biotech Corp (NASDAQ: LEGN)—that present potential buying opportunities. These companies are highlighted due to their Relative Strength Index (RSI) values being below 30, indicating they may be undervalued. The report details recent events and price movements for each stock, including analyst ratings and clinical trial setbacks.